The Biden administration announced plans to invest $10 billion in domestic manufacturing of critical medical supplies, including drugs and active pharmaceutical ingredients. The funding is intended to help address supply chain vulnerabilities exposed during the COVID-19 pandemic.
Shinpharma Inc. Canada.